Lupin launches generic conjunctivitis treatment medicine in US
The product is produced at Lupin's Pithampur manufacturing facility, it added. The medicine is generic equivalent of Novartis Corp's Vigamox Ophthalmic solution.
By PTI | Updated:
NEW DELHI: Domestic pharma major Lupin Ltd today said it has launched in the US market its generic version of Moxifloxacin Hydrochloride Ophthalmic solution used for treating bacterial conjunctivitis.
The launch follows receipt of approval from the US Food and Drug Administration ( USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 per cent, the company said in a statement.
The product is produced at Lupin's Pithampur manufacturing facility, it added.
The medicine is generic equivalent of Novartis Pharma Corp's Vigamox Ophthalmic solution.
Shares of Lupin were trading at Rs 1,063 apiece during mid-day trade, up 1.80 per cent from the previous close on BSE.
The launch follows receipt of approval from the US Food and Drug Administration ( USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 per cent, the company said in a statement.
The product is produced at Lupin's Pithampur manufacturing facility, it added.
The medicine is generic equivalent of Novartis Pharma Corp's Vigamox Ophthalmic solution.
Shares of Lupin were trading at Rs 1,063 apiece during mid-day trade, up 1.80 per cent from the previous close on BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
